TScan Therapeutics(US:TCRX)2025-05-06 12:08Financial Status and Future Plans - TScan's cash reserves of $290.1 million as of December 31, 2024, are expected to fund operations into Q1 2027[7,100] - TScan plans to launch a pivotal trial with topline readout in 2H27, targeting a >$1 billion addressable market across the US & EU[7,100] - TScan expects multiple clinical catalysts by the end of 2025, including launching a pivotal study and presenting two-year relapse data for the HEME program, and presenting safety and response data for multiplex therapy in solid tumors[5,8,98,101] HEME Program (ALLOHA Trial) - In the ALLOHA Phase 1 trial, 2 out of 26 (8%) treatment-arm subjects relapsed, compared to 4 out of 12 (33%) control-arm subjects[48] - Event-free survival strongly favors the treatment arm with a hazard ratio (HR) of 0.30[48] - Almost all subjects infused to date [19/22 (86.3%)] qualified for treatment with TSC-101[52] Solid Tumor Program (PLEXI-T Trial) - T-Plex enrollment will focus on five key indications with high unmet need: NSCLC (~63K potential U S patients), Sarcoma (~3K), Head & Neck (~15K), Anal & Genital (~4K), and Cervical (~7K)[88,89] - 15-60% of patients are currently eligible for multiplex TCR-T cell therapy with the 7 TCRs in the current PLEXI-T study[93]